Breast cancer (BC) is the most common cancer among young women and pregnant women.1 By 2022, anti-ERBB2 drugs had become the cornerstone of medical treatment for ERBB2-positive BCs, and their use during pregnancy, while rare, is expected to become more common. Here, ERBB2 is linked to breast carcinoma.